Source-grounded facts extracted from Monte Rosa Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Monte Rosa Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Monte Rosa Therapeutics, Inc. shareholders approved Election of three Class II directors: Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. at the 2026-06-11 meeting.
“The stockholders of the Company elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal.”
Monte Rosa Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026.”
Monte Rosa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 17, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended December 31, 2025.”
Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at $24.00 per share (effective 2026-01-08).
“On January 8, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 11,125,000 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a public offering price of $24.00 per share”
Jennifer Champoux changed role as Chief Operating Officer at Monte Rosa Therapeutics, Inc..
“On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024”
Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, as representative of the several underwriters valued at approximately $96.7 million (effective 2024-05-15).
“On May 15, 2024, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, as representative of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering”
Monte Rosa Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024.
“Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Owen Wallace resigned as Chief Scientific Officer at Monte Rosa Therapeutics, Inc..
“On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the "Company"), resigned from the Company effective May 17, 2024 (the “Effective Date”).”
Monte Rosa Therapeutics, Inc. reported financial results for full year and fourth quarter ended December 31, 2023.
“Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023.”
Monte Rosa Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $34.9 million.
“Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.”
Monte Rosa Therapeutics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $25.0 million (effective 2023-10-26).
“Monte Rosa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of pre-funded warrants to purchase 10,000,400 shares of the Company’s common stock”
Monte Rosa Therapeutics, Inc. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. valued at upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston (effective 2023-10-16).
“On October 16, 2023, Monte Rosa Therapeutics AG (“Monte Rosa AG,” hereinafter the “Company”), a wholly-owned subsidiary of Monte Rosa Therapeutics, Inc., F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US” and together with Roche Basel, “Roche”) entered into a Collaboration and License Agreement (the “Agreement”).”
Monte Rosa Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $35.2 million.
“Net loss for the second quarter of 2023 was $35.2 million”
Anthony M. Manning was appointed as Director at Monte Rosa Therapeutics, Inc..
“the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.”
Monte Rosa Therapeutics, Inc.: Amendment to Fourth Amended and Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law (effective 2023-06-14).
“As further described in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. On June 14, 2023, the Company filed a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.”
Monte Rosa Therapeutics, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
“The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: Votes Votes For Against Abstain 45,290,642 2,698 8,736”
Monte Rosa Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. at the 2023-06-14 meeting.
“The stockholders of the Company approved the amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. The results of the stockholders’ vote with respect to such approval were as follows: Votes Votes Broker For Against Abstain Non-votes 42,500,758 567,676 7,900 2,225,742”
Monte Rosa Therapeutics, Inc. shareholders approved Election of Class II Director Nominees at the 2023-06-14 meeting.
“The stockholders of the Company elected Andrew Schiff, M.D. and Chandra P. Leo as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until their successor have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Votes For Votes Withheld Broker Non-Votes Andrew Schiff, M.D. 41,135,067 1,941,267 2,225,742 Chandra P. Leo 42,883,895 192,439 2,225,742”
Monte Rosa Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $32 million.
“On May 11, 2023, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2023.”
Jan Skvarka was appointed as Director at Monte Rosa Therapeutics, Inc..
“the Board appointed Jan Skvarka, Ph.D., MBA to join the Board, effective as of March 23, 2023.”
Monte Rosa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
“On March 16, 2023, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.